Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | VNN1 | O95497 | 6/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 4/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MMP10 | P09238 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168153 | 0.92 | VNN1 (0.50) | P2RX7VNN1RPS6KB1AURKAAURKB | |
| SCHEMBL13593907 | 0.92 | P2RX7 (0.43) | P2RX7VNN1RPS6KB1AURKAAURKB | |
| SCHEMBL10162782 | 0.89 | P2RX7 (0.47) | P2RX7VNN1RPS6KB1AURKAAURKB | |
| SCHEMBL10162599 | 0.89 | MMP13 (0.51) | RPS6KB1AURKAAURKBMMP13MMP10 | |
| SCHEMBL10168157 | 0.88 | P2RX7 (0.43) | P2RX7VNN1RPS6KB1AURKAAURKB | |
| SCHEMBL10168688 | 0.88 | GRM4 (0.46) | RPS6KB1AURKAAURKBMMP13 | |
| SCHEMBL10168167 | 0.87 | P2RX7 (0.44) | P2RX7VNN1RPS6KB1AURKAAURKB | |
| SCHEMBL13593039 | 0.86 | RPS6KB1 (0.43) | P2RX7VNN1RPS6KB1AURKAAURKB | |
| SCHEMBL10209881 | 0.85 | P2RX7 (0.45) | P2RX7VNN1RPS6KB1AURKAAURKB | |
| SCHEMBL10168149 | 0.84 | P2RX7 (0.56) | P2RX7VNN1RPS6KB1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | P2RX7 3795/4885VNN1 312/4885RPS6KB1 2535/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | P2RX7 3795/4885VNN1 312/4885RPS6KB1 2535/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | P2RX7 3795/4885VNN1 312/4885RPS6KB1 2535/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | P2RX7 3795/4885VNN1 312/4885RPS6KB1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.